News
GE HealthCare awarded US$44m grant to develop AI-assisted ultrasound technology
Ultrasound technologies are used to determine foetal health markers and conditions like gestational age and foetal viability
GE HealthCare has received a US$44m grant from the Bill & Melinda Gates Foundation to develop an AI-assisted ultrasound technology to address maternal and foetal health diseases.
These tools are hoped to aid healthcare professionals with clinical decision information to support more effective obstetric and lung screening ultrasound scans across maternal and foetal care as well as paediatric lung health, with a goal of expanding access to low-and-middle income countries.
Caption Health, an AI company acquired by GE HealthCare in February, will design the technology to run across a range of ultrasound devices and probes, including lower-cost handheld devices.
“We are proud and excited to have received this grant from the Bill & Melinda Gates Foundation to make ultrasound more accessible in low-and-middle income countries,” said Roland Rott, president and CEO, ultrasound, GE HealthCare.
“Ultrasound is an essential tool for screening and diagnosis of various medical conditions, including the health of expectant mothers and managing respiratory diseases.
“However, a key limitation is the guidance of lesser-skilled users to effectively apply affordable point-of-care ultrasound in their care environment.
“This grant will help bring Caption Health’s leading AI technology customised to more users, and therefore contribute to increased access to higher-quality medical care.”
Maternal and child mortality is a critical healthcare issue around the world. In 2020, almost 800 women died every day from preventable causes linked to pregnancy and childbirth, with approximately 95 per cent of all maternal deaths occurring in low-and-middle income countries.
In 2019, almost two and a half million children around the world died in their first month of life.
Ultrasound technologies are used in maternal care to determine foetal health markers and conditions like gestational age, foetal presentation, multiple gestation, foetal viability, umbilical blood flow, and ectopic pregnancy.
For children younger than five years old, pneumonia is the leading cause of death worldwide. Because symptoms of pneumonia can develop suddenly, early diagnosis is vital to effective treatment and preventing complications.
Point of care lung ultrasound can provide physicians with a view of the entire lung, is easily repeatable and can diagnose pneumonia with greater accuracy compared with a bedside chest X-ray.
In 2020, Caption Health received a grant from the Bill & Melinda Gates Foundation to support the development of innovative AI technology for lung ultrasound.
Karley Yoder, chief digital officer, ultrasound, GE HealthCare and general manager, Caption Health, said: “Caption Health AI applications are designed to guide healthcare professionals, step-by-step, during an ultrasound exam to help them capture and interpret high-quality ultrasound images.
“We are thankful for the continued support of the Bill & Melinda Gates Foundation, which enables us to expand the development of our existing lung ultrasound project and also broaden the reach of this powerful, novel technology to help provide care to mothers and children.”
Currently, Caption Health offers Cardiac Guidance software, which is FDA cleared.
With the support of the Bill & Melinda Gates Foundation grant, the company says it will develop multiple lung ultrasound and obstetric algorithms through clinical validation and regulatory submissions.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






